Salveen Richter is a Wall Street analyst working for Goldman Sachs. Salveen has covered 43 stocks with a 43.64% success rate and an average return of 0.34%.

Mar 23, 2022 · In the latest episode of Exchanges at Goldman Sachs, Salveen Richter, Lead Analyst for the U.S. Biotechnology Sector in Goldman Sachs Research, explains how new innovations in gene editing are transforming the future of medicine and the greater biotech investment landscape.

Salveen Richter is a 4.41-star Wall Street Analyst at Goldman Sachs. Salveen Richter's focuses on the Healthcare sector and covers 84 stocks with a 40.86% success rate.

Jan 29, 2025 · Analyst Salveen Richter, currently employed at GOLDMAN SACHS, carries an average stock price target met ratio of 65.31% that have a potential upside of 34.24% achieved within 266 days. Salveen Richter ’s has documented …

Mar 23, 2022 · So I've asked Salveen Richter, our lead biotechnology research analyst in the US, to join us to walk through the latest developments, the most promising applications, and the outlook for broader adoption. Salveen, welcome to the program. Allison, thanks for having me. So let's start with the basics.

Apr 26, 2023 · Healthcare — one of the largest sectors of the U.S. economy — is among the many industries with significant opportunities for the use of artificial intelligence (AI) and machine learning (ML), says Salveen Richter, lead analyst for the U.S. biotechnology sector at Goldman Sachs Research.

Jan 3, 2024 · Goldman Sachs analyst Salveen Richter maintained a Buy rating on Agios Pharma (AGIO – Research Report) today. The company’s shares opened today at $23.58. According to TipRanks, Richter is a...

Salveen Richter Analyst Color Get additional color on Salveen Richter's coverage of popular stocks

Learn more about the Department of Biomedical Engineering leadership team, including faculty and advisory board members.